Acute interruption of arterial blood flow to the extremities is often associated with significant morbidity and mortality. Broad spectrum mitogenic and non mitogenic activities of FGFs inspired us to study its protect...Acute interruption of arterial blood flow to the extremities is often associated with significant morbidity and mortality. Broad spectrum mitogenic and non mitogenic activities of FGFs inspired us to study its protecting effects on tissue injuries in ischemia reperfusion condition. We found that systemic administration of aFGF after reperfusion onset prevented severe skeletal muscle injuries. In rats treated with aKGF, the tissue edema was reduced significantly, the tissue viability was increased, and the muscle fibers contained more succinate dehydrogenase (SDH) and adenosine triphosphatasc (ATPase). The pathological results supported the concept of improved prevention with aFGF treatment. The possible tissue protection by aFGF may come from its ability to regulate the concentration of evtra- and intracellular calcium ion. Besides, it may moderate other Ca2+ dependent enzyme conversion processes. Also, it may take part in the vascular tone regulation under ischemia and reperfusion conditions. These results suggest further study of tissue ischemia prevention with FGF and its possible mechanisms in the future.展开更多
目的:测定大鼠摄食量的变化来鉴定aFGF分子中具有调节摄食行为的活性部位,并进一步经皮下注射有活性的片段,观察对大鼠夜间摄食的影响,以此确定该活性片段外周给药的有效性.方法:将设计好的七种aFGF分子片段aFGF-(1-15),[D-Trp6]-aFGF-(...目的:测定大鼠摄食量的变化来鉴定aFGF分子中具有调节摄食行为的活性部位,并进一步经皮下注射有活性的片段,观察对大鼠夜间摄食的影响,以此确定该活性片段外周给药的有效性.方法:将设计好的七种aFGF分子片段aFGF-(1-15),[D-Trp6]-aFGF-(1-15),[desaminoPhe1.D-Trp6]-aFGF-(1-15),[desaminoPhe1.Lys(ε-myristyl)16]-aFGF-(1-16),[Lys(ε-myristyl)16]-aFGF-(1-16),[D-Trp6.Lys(ε-myristyl)16]-aFGF-(1-16)及[Ala16]aFGF-(1-29),在无麻醉下于18:30-19:00从第三脑室留置的不锈钢导管微量注射,然后在19:00,22:00及07:00的时间点测定饲料箱内粉末饲料,分别计算3h(19:00-22:00)及12h(19:00-7:00)的摄食量.然后将发现具有生物活性的aFGF-(1-15)及[Ala16]aFGF-(1-29)两个片段经皮下注射给药,测定夜间摄食量.结果:aFGF-(1-15)以每只大鼠200ng脑室内给与后对摄食没有影响,以每只大鼠400ng脑室内给与后减少了大鼠的夜间摄食量(3h:3.0±0.2 vs 2.1±0.2;12h:18.5±0.5 vs 16.1±0.5,P<0.01);[Ala16]aFGF-(1-29)经脑室内投与,无论是在每只大鼠200ng(3h:4.9±0.2vs3.4±0.2;12h:19.3±1.2vs17.3±1.1,P<0.01);还是每只大鼠400ng给药均减少了大鼠的夜间摄食量(3h:3.6±0.1 vs 1.6±0.2;12h:19.9±0.8 vs 16.4±1.6,P<0.01),并且与aFGF-(1-15)相比,[Ala16]aFGF-(1-29)抑制摄食作用更明显;其余五种aFGF片段脑室内注射无论每只大鼠200ng还是在每只大鼠400ng,对大鼠夜间摄食均没有影响.aFGF-(1-15)和[Ala16]aFGF-(1-29)以80、100、300μg/kg大鼠皮下注射,其中仅[Ala16]aFGF-(1-29),300μg/kg皮下注射减少了大鼠的夜间摄食量(3h:3.9±0.2 vs 2.1±0.3;12h:19.8±0.5 vs 11.2±0.8,P<0.01),其余种类和剂量对大鼠夜间摄食均没有影响.结论:aFGF氨基酸序列的N末端及用丙氨酸代替aFGF氨基末端中半胱氨酸残基对摄食调节发挥重要作用.而第6位甘氨酸被右旋-色氨酸替代,第1位苯丙氨酸去氨基,第16位半胱氨酸被赖氨酸(ε-十四烷基)所代替,均没有摄食调节活性.部分活性片段外周给药同样可以发挥其生物活性.展开更多
文摘Acute interruption of arterial blood flow to the extremities is often associated with significant morbidity and mortality. Broad spectrum mitogenic and non mitogenic activities of FGFs inspired us to study its protecting effects on tissue injuries in ischemia reperfusion condition. We found that systemic administration of aFGF after reperfusion onset prevented severe skeletal muscle injuries. In rats treated with aKGF, the tissue edema was reduced significantly, the tissue viability was increased, and the muscle fibers contained more succinate dehydrogenase (SDH) and adenosine triphosphatasc (ATPase). The pathological results supported the concept of improved prevention with aFGF treatment. The possible tissue protection by aFGF may come from its ability to regulate the concentration of evtra- and intracellular calcium ion. Besides, it may moderate other Ca2+ dependent enzyme conversion processes. Also, it may take part in the vascular tone regulation under ischemia and reperfusion conditions. These results suggest further study of tissue ischemia prevention with FGF and its possible mechanisms in the future.
文摘目的:测定大鼠摄食量的变化来鉴定aFGF分子中具有调节摄食行为的活性部位,并进一步经皮下注射有活性的片段,观察对大鼠夜间摄食的影响,以此确定该活性片段外周给药的有效性.方法:将设计好的七种aFGF分子片段aFGF-(1-15),[D-Trp6]-aFGF-(1-15),[desaminoPhe1.D-Trp6]-aFGF-(1-15),[desaminoPhe1.Lys(ε-myristyl)16]-aFGF-(1-16),[Lys(ε-myristyl)16]-aFGF-(1-16),[D-Trp6.Lys(ε-myristyl)16]-aFGF-(1-16)及[Ala16]aFGF-(1-29),在无麻醉下于18:30-19:00从第三脑室留置的不锈钢导管微量注射,然后在19:00,22:00及07:00的时间点测定饲料箱内粉末饲料,分别计算3h(19:00-22:00)及12h(19:00-7:00)的摄食量.然后将发现具有生物活性的aFGF-(1-15)及[Ala16]aFGF-(1-29)两个片段经皮下注射给药,测定夜间摄食量.结果:aFGF-(1-15)以每只大鼠200ng脑室内给与后对摄食没有影响,以每只大鼠400ng脑室内给与后减少了大鼠的夜间摄食量(3h:3.0±0.2 vs 2.1±0.2;12h:18.5±0.5 vs 16.1±0.5,P<0.01);[Ala16]aFGF-(1-29)经脑室内投与,无论是在每只大鼠200ng(3h:4.9±0.2vs3.4±0.2;12h:19.3±1.2vs17.3±1.1,P<0.01);还是每只大鼠400ng给药均减少了大鼠的夜间摄食量(3h:3.6±0.1 vs 1.6±0.2;12h:19.9±0.8 vs 16.4±1.6,P<0.01),并且与aFGF-(1-15)相比,[Ala16]aFGF-(1-29)抑制摄食作用更明显;其余五种aFGF片段脑室内注射无论每只大鼠200ng还是在每只大鼠400ng,对大鼠夜间摄食均没有影响.aFGF-(1-15)和[Ala16]aFGF-(1-29)以80、100、300μg/kg大鼠皮下注射,其中仅[Ala16]aFGF-(1-29),300μg/kg皮下注射减少了大鼠的夜间摄食量(3h:3.9±0.2 vs 2.1±0.3;12h:19.8±0.5 vs 11.2±0.8,P<0.01),其余种类和剂量对大鼠夜间摄食均没有影响.结论:aFGF氨基酸序列的N末端及用丙氨酸代替aFGF氨基末端中半胱氨酸残基对摄食调节发挥重要作用.而第6位甘氨酸被右旋-色氨酸替代,第1位苯丙氨酸去氨基,第16位半胱氨酸被赖氨酸(ε-十四烷基)所代替,均没有摄食调节活性.部分活性片段外周给药同样可以发挥其生物活性.